Absence of COVID-19 Disease Among Chronically Ventilated Nursing Home Patients

ObjectiveTo describe the experience of COVID-19 disease among chronically ventilated and nonventilated nursing home patients living in 3 separate nursing homes.DesignObservational study of death, respiratory illness and COVID-19 polymerase chain reaction (PCR) results among residents and staff during nursing home outbreaks in 2020.Setting and Participants93 chronically ventilated nursing home patients and 1151 nonventilated patients living among 3 separate nursing homes on Long Island, New York, as of March 15, 2020. Illness, PCR results, and antibody studies among staff are also reported.MeasurementsData were collected on death rate among chronically ventilated and nonventilated patients between March 15 and May 15, 2020, compared to the same time in 2019; prevalence of PCR positivity among ventilated and nonventilated patients in 2020; reported illness, PCR positivity, and antibody among staff.ResultsTotal numbers of deaths among chronically ventilated nursing home patients during this time frame were similar to the analogous period 1 year earlier (9 of 93 in 2020 vs 8 of 100 in 2019, P = .8), whereas deaths among nonventilated patients were greatly increased (214 of 1151 in 2020 vs 55 of 1189 in 2019, P < .001). No ventilated patient deaths were clinically judged to be COVID-19 related. No clusters of COVID-19 illness could be demonstrated among ventilated patients. Surveillance PCR testing of ventilator patients failed to reveal COVID-19 positivity (none of 84 ventilator patients vs 81 of 971 nonventilator patients, P < .002). Illness and evidence of COVID-19 infection was demonstrated among staff working both in nonventilator and in ventilator units.Conclusions and ImplicationsCOVID-19 infection resulted in illness and death among nonventilated nursing home residents as well as among staff. This was not observed among chronically ventilated patients. The mechanics of chronic ventilation appears to protect chronically ventilated patients from COVID-19 disease.     

慢性肾功能衰竭患者血清C—PTH变化与并发症的关系探讨

探讨慢性肾功能衰竭(CRF)患者血清羧基端甲状旁腺素(C-PTH)的变化及与钙磷代谢、高血压和贫血的关系。方法44例CRF患者用放免法测定血清C-PTH,血清尿素氮(BUN)、血清肌酐(Scr)、血清钙(Ca     

肾衰透析患者拔牙的临床研究

目的 :探讨肾衰透析患者拔牙的安全性。　方法 :对 42例肾衰血透患者行 98次拔牙手术 ,共拔除患牙 12 2颗 ,术前采取全口洁治、服用抗生素、控制血压等措施 ,术后加强局部止血处理 ,预防出血、感染及心血管系统等并发症的发生。　结果 :透析组术后出血 44次 ,拔牙创口血块充盈不良或脱落 2 7次 ;对照组分别为 4和 5次 (94次手术 ,P<0 .0 5 )。拔牙创口定期观察 1个月 ,均愈合良好。　结论 :慢性肾衰患者通过透析 ,尿毒症得到控制和改善时 ,在作好围拔牙期处理的情况下 ,行拔牙手术是安全可行的     

止泻颗粒剂治疗小儿消化不良性肠炎136例

运用止泻颗粒剂与思密达作对照治疗小儿消化不良性肠炎,治疗组136例,对照组80例,2组总有效率分别为95．5％,37．5％,疗效比较具有显著性差异,P＜0．01。     

细胞因子在清肝化瘀汤治疗慢性粒细胞性白血病中的研究

目的观察中药清肝化瘀汤治疗慢性粒细胞性白血病(慢性期)的疗效,并探讨细胞因子水平变化的意义。方法收集45例慢性粒细胞性白血病慢性期患者(治疗组),用清肝化瘀汤治疗,观察患者的临床疗效、细胞因子水平。另用20名正常人作为对照(对照组)。结果治疗组完全缓解率40％,部分缓解率46.7％,总有效率86.7％。治疗组细胞因子水平中白介素2、可溶性白介素2受体、肿瘤坏死因子a治疗前后有显著差异(P<0.05);干扰素γ水平变化无显著差异。且与正常对照组比较无显著差异(P>0.05)。结论清肝化瘀汤有清热泻肝解毒、活血化瘀消癥的功效,研究结果显示,该药对慢性粒细胞性白血病慢性期(肝热血瘀型)疗效确切,其作用机理可能与改善细胞因子水平有关。     

Gel tópico de amitriptilina al 2% y ketamina al 0,5% para el tratamiento de la eritromelalgia: reporte de un caso con respuesta positiva al dolor

Erythromelalgia (EM) is a rare autosomal dominant neuropathy characterized by the combination of severe burning pain and erythematous warm extremities. Chronic pain control is most often unsuccessful and a completely effective therapy is yet to be identified. Recent studies have reported significant improvements in pain management using a combination of amitriptyline and ketamine in a topical formulation. We describe a 1-year follow-up pain control success case of a male patient with EM, proposed for topical use of a 2% Amitriptyline and 0.5% Ketamine gel.